<DOC>
	<DOCNO>NCT02382575</DOCNO>
	<brief_summary>The vast majority child idiopathic nephrotic syndrome respond well corticosteroid treatment . However , many 20 % experience complicate course steroid resistance ( SRNS ) . Repeated prolonged course steroid child often result long-term complication . The goal treatment reduce rate relapse , cumulative dose corticosteroid , incidence serious complication . In order minimize side effect steroid therapy , different steroid spar agent cyclophosphamide , calcineurin inhibitor ( CNI ) , levamisole , mycophenolate mofetil ( MMF ) use SRNS . Whereas CNI usually consider steroid spar drug class first choice , rituximab increasingly use alternative minimize CNI toxicity . Various prospective study suggest Rituximab , B cell deplete monoclonal antibody , could safe effective alternative steroid immunosuppressant achieve maintain remission population . Rituximab infusion show efficacious 6 12 month side effect profile observe date benign . Studies compare usefulness agent lack . In proposed randomized control trial , investigator want compare efficacy safety CNI Rituximab treat child SRNS .</brief_summary>
	<brief_title>Efficacy Safety Rituximab That Calcineurin Inhibitors Children With Steroid Resistant Nephrotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Children 3 16 year SRNS Minimal Change disease/Messengioproliferative glomerulonephritis/Focal segmental glomerulosclerosis per Kidney Biopsy report . Estimated glomerular filtration rate ( eGFR ) &gt; 80 ml/min per 1.73 m2 study entry . Not receive steroid spar agent previously . Parents willing give inform write consent . Ability swallow tablet Known etiology ( e.g. , lupus erythematosus , IgA nephropathy , amyloidosis , malignancy , secondary form NS ) Patients severe leucopenia ( leucocytes &lt; 3.0× 1000 cells/mm3 ) , severe anemia ( haemoglobin &lt; 8.9 g/dl ) , thrombocytopenia ( platelet &lt; 100.0 × 1000 cells/mm3 ) derange liver function test ( AST ALT &gt; 50 IU/L ) enrolment . Known active chronic infection ( tuberculosis , HIV , hepatitis B C ) Live vaccination within 1 mo</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>